Literature DB >> 23873577

Foraging activity is reduced in a mouse model of depression.

C R Yang1, Z G Zhang, Y Y Bai, H Fiona Zhou, L Zhou, C S Ruan, F Li, C Q Li, H Y Zheng, L J Shen, X F Zhou.   

Abstract

Depression interferes with the human ability to make decisions. Multiple criteria have been adopted for the diagnosis of depression in humans, but no clear indicators are available in animal models to reflect the depressive mood, involving higher cognitive functions. The act of foraging is a species-specific behaviour which is believed to involve the decision-making and higher cognitive functions. We previously established a method to detect the foraging behaviour of rodents, in which our results demonstrated that NMDA and dopamine receptors were involved. Conversely, increased NMDA receptors and reduced dopamine have been reported in depression model rodents. However, we hypothesise that foraging activities may also be impaired in depression. To test the theory, we successfully established a mouse model of depression using the chronic unpredictable mild stress (CUMS) paradigm. Most interestingly, the food foraging activity of mice after CUMS was significantly reduced. In addition, the treatment of anti-depressant fluoxetine reversed most depressive symptoms and reduced glial fibrillary associated protein (GFAP) expression in the hippocampus, but was less effective in the reduction of foraging activities. However, clozapine reversed all symptoms of CUMS-exposed mice including reduction of GFAP expression in the hippocampus and impaired foraging activity. Our findings of GFAP expression as a marker to validate the CUMS protocol provide further validation of our hypothesis, that the reduced food foraging is probably a new behavioural finding of depression in which the serotoninergic system could not be singly involved. Our study suggests that NMDA receptors, serotoninergic and dopaminergic systems are differentially involved in these food foraging behaviours. Our data suggest that the foraging test in rodents can be a useful tool to assess the ability of decision-making in depression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23873577     DOI: 10.1007/s12640-013-9411-6

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  62 in total

1.  Phasic nucleus accumbens dopamine release encodes effort- and delay-related costs.

Authors:  Jeremy J Day; Joshua L Jones; R Mark Wightman; Regina M Carelli
Journal:  Biol Psychiatry       Date:  2010-05-10       Impact factor: 13.382

2.  Decision-making cognition in mania and depression.

Authors:  F C Murphy; J S Rubinsztein; A Michael; R D Rogers; T W Robbins; E S Paykel; B J Sahakian
Journal:  Psychol Med       Date:  2001-05       Impact factor: 7.723

3.  Prefrontostriatal circuitry regulates effort-related decision making.

Authors:  Wolfgang Hauber; Susanne Sommer
Journal:  Cereb Cortex       Date:  2009-01-08       Impact factor: 5.357

4.  The mesocortical dopamine projection to anterior cingulate cortex plays no role in guiding effort-related decisions.

Authors:  M E Walton; P L Croxson; M F S Rushworth; D M Bannerman
Journal:  Behav Neurosci       Date:  2005-02       Impact factor: 1.912

Review 5.  Stress models of depression: forming genetically vulnerable strains.

Authors:  Fritz A Henn; Barbara Vollmayr
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

6.  Differential involvement of serotonin and dopamine systems in cost-benefit decisions about delay or effort.

Authors:  F Denk; M E Walton; K A Jennings; T Sharp; M F S Rushworth; D M Bannerman
Journal:  Psychopharmacology (Berl)       Date:  2004-12-10       Impact factor: 4.530

7.  The psychopharmacology of energy and fatigue.

Authors:  Stephen M Stahl
Journal:  J Clin Psychiatry       Date:  2002-01       Impact factor: 4.384

Review 8.  Gliogenesis and glial pathology in depression.

Authors:  G Rajkowska; J J Miguel-Hidalgo
Journal:  CNS Neurol Disord Drug Targets       Date:  2007-06       Impact factor: 4.388

9.  Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed.

Authors:  B C Beats; B J Sahakian; R Levy
Journal:  Psychol Med       Date:  1996-05       Impact factor: 7.723

10.  Impaired social decision making in patients with major depressive disorder.

Authors:  Hui-Jun Zhang; Delin Sun; Tatia M C Lee
Journal:  Brain Behav       Date:  2012-07       Impact factor: 2.708

View more
  6 in total

1.  Enhanced aggressive behaviour in a mouse model of depression.

Authors:  C R Yang; Y Y Bai; C S Ruan; H F Zhou; D Liu; X F Wang; L J Shen; H Y Zheng; X F Zhou
Journal:  Neurotox Res       Date:  2014-11-04       Impact factor: 3.911

2.  Injection of Anti-proBDNF in Anterior Cingulate Cortex (ACC) Reverses Chronic Stress-Induced Adverse Mood Behaviors in Mice.

Authors:  C R Yang; Y Y Bai; C S Ruan; F H Zhou; F Li; C Q Li; X F Zhou
Journal:  Neurotox Res       Date:  2016-12-12       Impact factor: 3.911

3.  ProBDNF Signaling Regulates Depression-Like Behaviors in Rodents under Chronic Stress.

Authors:  Yin-Yin Bai; Chun-Sheng Ruan; Chun-Rui Yang; Jia-Yi Li; Zhi-Long Kang; Li Zhou; Dennis Liu; Yue-Qing Zeng; Ting-Hua Wang; Chang-Fu Tian; Hong Liao; Larisa Bobrovskaya; Xin-Fu Zhou
Journal:  Neuropsychopharmacology       Date:  2016-06-17       Impact factor: 7.853

Review 4.  Dysregulation of brain dopamine systems in major depressive disorder.

Authors:  Nella C Delva; Gregg D Stanwood
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-16

5.  Roles of NMDA and dopamine in food-foraging decision-making strategies of rats in the social setting.

Authors:  Fang Li; Wen-Yu Cao; Fu-Lian Huang; Wen-Jing Kang; Xiao-Lin Zhong; Zhao-Lan Hu; Hong-Tao Wang; Juan Zhang; Jian-Yi Zhang; Ru-Ping Dai; Xin-Fu Zhou; Chang-Qi Li
Journal:  BMC Neurosci       Date:  2016-01-11       Impact factor: 3.288

Review 6.  Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis.

Authors:  Ronald Kim; Kati L Healey; Marian T Sepulveda-Orengo; Kathryn J Reissner
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-10-06       Impact factor: 5.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.